Emerging epigenetic-modulating therapies in lymphoma Review
| Authors: | Sermer, D.; Pasqualucci, L.; Wendel, H. G.; Melnick, A.; Younes, A. |
| Review Title: | Emerging epigenetic-modulating therapies in lymphoma |
| Abstract: | Despite considerable advances in the treatment of lymphoma, the prognosis of patients with relapsed and/or refractory disease continues to be poor; thus, a continued need exists for the development of novel approaches and therapies. Epigenetic dysregulation might drive and/or promote tumorigenesis in various types of malignancies and is prevalent in both B cell and T cell lymphomas. Over the past decade, a large number of epigenetic-modifying agents have been developed and introduced into the clinical management of patients with haematological malignancies. In this Review, we provide a concise overview of the most promising epigenetic therapies for the treatment of lymphomas, including inhibitors of histone deacetylases (HDACs), DNA methyltransferases (DNMTs), enhancer of zeste homologue 2 (EZH2), bromodomain and extra-terminal domain proteins (BETs), protein arginine N-methyltransferases (PRMTs) and isocitrate dehydrogenases (IDHs), and highlight the most promising future directions of research in this area. © 2019, Springer Nature Limited. |
| Journal Title: | Nature Reviews Clinical Oncology |
| Volume: | 16 |
| Issue: | 8 |
| ISSN: | 1759-4774 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2019-08-01 |
| Start Page: | 494 |
| End Page: | 507 |
| Language: | English |
| DOI: | 10.1038/s41571-019-0190-8 |
| PUBMED: | 30837715 |
| PROVIDER: | scopus |
| PMCID: | PMC6650343 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 30 August 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work